Search for Clinical Trial Results
Clear Cell Renal Cell Carcinoma - 27 Studies Found
Status | Study |
Recruiting |
Study Name: Study of Neoadjuvant Nivolumab in Patients With Non-metastatic Stage II-IV Clear Cell Renal Cell Carcinoma Condition: Clear Cell Renal Cell Carcinoma Date: 2015-10-06 Interventions: Drug: Nivolumab 3 mg/kg, IV (in the vein) on day 1 of each 2-week cycle, for a total of 3 doses prior to |
Completed |
Study Name: Safety and Activity of G-202 in Patients With Clear Cell Renal Cell Carcinoma That Expresses PSMA Condition: Clear Cell Renal Cell Carcinoma Date: 2015-11-16 Interventions: Drug: G-202 G-202 administered by intravenous infusion on Days 1, 2 and 3 of each 28-day cycle until dis |
Recruiting |
Study Name: Nivolumab and Stereotactic Ablative Radiation Therapy (SAbR) for Metastatic Clear Cell Renal Cell Carcinoma Condition: Metastatic Clear Cell Renal Cell Carcinoma Date: 2016-05-19 Interventions:
|
Completed |
Study Name: Validation of a Predictive Nomogram of Response or Resistance to Targeted Therapies in Metastatic Clear Cell Renal Cell Carcinoma Condition: Metastatic Clear Cell Renal Cell Carcinoma Date: 2016-07-26 Interventions: Drug: Sunitinib |
Active, not recruiting |
Study Name: Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025) Condition: Advanced or Metastatic (Medically or Surgically Unresectable) Clear-cell Renal Cell Carcinoma Date: 2012-08-16 Interventions:
|
Recruiting |
Study Name: SLM + Axitinib for Clear Cell RCC Condition: Advanced Metastatic Clear Cell Renal Cell Carcinoma (CCRCC) Date: 2015-08-17 Interventions:
|
Recruiting |
Study Name: Addition of X4P-001 to Nivolumab Treatment in Patients With Renal Cell Carcinoma Condition: Clear Cell Renal Cell Carcinoma Date: 2016-09-30 Interventions:
|
Not yet recruiting |
Study Name: Investigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation in Patients With Metastatic Clear-Cell RCC (ccRCC) Who Have Failed Treatment With Single-Agent Nivolumab Condition:
|
Completed |
Study Name: Effect of Sorafenib on ccRCC Uptake of Radiolabeled Bevacizumab or cG250 Condition: Clear Cell Renal Cell Carcinoma Date: 2008-01-03 Interventions:
|
Completed |
Study Name: Neoadjuvant Sunitinib Treatment for Metastatic Clear Cell Renal Cell Carcinoma (RCC) Condition:
Date: 2010-02-12 Interventions: Drug: Sunitinib 50mg daily(4 weeks on & 2 weeks off), 2 cycles, until progression or unacceptable to |